Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DCTHNASDAQ:NPCENASDAQ:SMLRNASDAQ:STIM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDCTHDelcath Systems$16.19-1.3%$13.20$6.33▼$18.23$563.83M0.72374,630 shs524,173 shsNPCENeuroPace$12.46-1.6%$12.80$5.45▼$18.98$408.68M2.04157,580 shs761,185 shsSMLRSemler Scientific$41.32-4.8%$36.21$21.77▼$81.56$460.80M1.33493,207 shs857,363 shsSTIMNeuronetics$3.85-3.0%$4.08$0.52▼$5.92$261.31M1.92752,555 shs395,955 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDCTHDelcath Systems-1.34%-6.09%+34.92%+16.35%+120.27%NPCENeuroPace-1.58%-31.27%+7.23%-0.80%+75.74%SMLRSemler Scientific-4.77%-7.95%+16.82%+1.70%+42.48%STIMNeuronetics-3.02%-3.99%-13.48%-10.05%+85.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDCTHDelcath Systems3.6003 of 5 stars3.55.00.00.03.92.50.6NPCENeuroPace2.2879 of 5 stars2.43.00.00.02.54.20.6SMLRSemler Scientific2.7906 of 5 stars3.52.00.00.02.62.51.3STIMNeuronetics2.7768 of 5 stars3.34.00.00.03.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDCTHDelcath Systems 3.00Buy$24.0048.24% UpsideNPCENeuroPace 2.83Moderate Buy$15.5024.40% UpsideSMLRSemler Scientific 3.00Buy$71.0071.83% UpsideSTIMNeuronetics 2.67Moderate Buy$5.5042.86% UpsideCurrent Analyst Ratings BreakdownLatest STIM, DCTH, NPCE, and SMLR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025NPCENeuroPaceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$18.005/23/2025DCTHDelcath SystemsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $29.005/14/2025NPCENeuroPaceJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$14.00 ➝ $16.005/14/2025NPCENeuroPaceCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$17.00 ➝ $17.003/7/2025DCTHDelcath SystemsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $24.003/5/2025NPCENeuroPaceCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$19.00 ➝ $20.003/5/2025STIMNeuroneticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $8.00(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDCTHDelcath Systems$53.85M10.47N/AN/A$0.72 per share22.49NPCENeuroPace$84.31M4.85N/AN/A$0.79 per share15.77SMLRSemler Scientific$49.23M9.36$2.44 per share16.95$10.45 per share3.95STIMNeuronetics$89.45M2.83N/AN/A$1.18 per share3.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDCTHDelcath Systems-$47.68M-$0.50N/AN/AN/A-150.70%-338.16%-104.02%8/4/2025 (Estimated)NPCENeuroPace-$32.96M-$0.84N/AN/AN/A-36.74%-205.41%-28.29%8/12/2025 (Estimated)SMLRSemler Scientific$20.58M-$2.618.42∞N/A72.65%50.77%47.04%8/4/2025 (Estimated)STIMNeuronetics-$30.19M-$1.31N/AN/AN/A-50.09%-141.24%-32.77%8/11/2025 (Estimated)Latest STIM, DCTH, NPCE, and SMLR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025NPCENeuroPace-$0.26-$0.21+$0.05-$0.21$21.85 million$22.52 million5/13/2025Q1 2025SMLRSemler ScientificN/A-$0.76N/A-$6.74N/A$8.84 million5/8/2025Q1 2025DCTHDelcath Systems$0.10$0.03-$0.07$0.03$16.83 million$19.80 million5/6/2025Q1 2025STIMNeuronetics-$0.13-$0.21-$0.08-$0.21$29.07 million$31.98 million3/6/2025Q4 2024DCTHDelcath Systems-$0.10-$0.11-$0.01-$0.11$14.96 million$15.10 million3/4/2025Q4 2024NPCENeuroPace-$0.25-$0.18+$0.07-$0.18$21.14 million$21.47 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDCTHDelcath SystemsN/AN/AN/AN/AN/ANPCENeuroPaceN/AN/AN/AN/AN/ASMLRSemler ScientificN/AN/AN/AN/AN/ASTIMNeuroneticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDCTHDelcath SystemsN/A1.341.03NPCENeuroPace6.035.594.77SMLRSemler ScientificN/A3.143.09STIMNeuronetics4.903.162.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDCTHDelcath Systems61.12%NPCENeuroPace78.83%SMLRSemler Scientific49.37%STIMNeuronetics53.59%Insider OwnershipCompanyInsider OwnershipDCTHDelcath Systems17.40%NPCENeuroPace22.20%SMLRSemler Scientific30.20%STIMNeuronetics8.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDCTHDelcath Systems6034.83 million26.24 millionOptionableNPCENeuroPace17032.80 million23.22 millionOptionableSMLRSemler Scientific12011.15 million6.47 millionNot OptionableSTIMNeuronetics18065.82 million27.37 millionOptionableSTIM, NPCE, DCTH, and SMLR HeadlinesRecent News About These CompaniesNeuronetics, Inc. (NASDAQ:STIM) EVP Sells $826,074.20 in StockMay 15, 2025 | insidertrades.comBalyasny Asset Management L.P. Grows Position in Neuronetics, Inc. (NASDAQ:STIM)May 15, 2025 | marketbeat.comNeuronetics Launches First Inaugural National TMS Therapy Awareness Day During Mental Health Awareness MonthMay 14, 2025 | tmcnet.comQ2 EPS Estimates for Neuronetics Reduced by William BlairMay 11, 2025 | marketbeat.comNeuronetics Announces Inducement Awards for New Team MembersMay 10, 2025 | msn.comNeuronetics, Inc. (NASDAQ:STIM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$6.83May 9, 2025 | finance.yahoo.comNeuronetics (NASDAQ:STIM) Posts Quarterly Earnings Results, Misses Expectations By $0.08 EPSMay 8, 2025 | marketbeat.comRenaissance Technologies LLC Has $255,000 Position in Neuronetics, Inc. (NASDAQ:STIM)May 8, 2025 | marketbeat.comEarnings call transcript: Neuronetics Q1 2025 misses EPS, stock drops 22%May 7, 2025 | investing.comNeuronetics Reports 84% Revenue Growth in Q1 2025 Driven by Greenbrook AcquisitionMay 7, 2025 | nasdaq.comNeuronetics Reports 84% Revenue Growth in Q1 2025 Driven by Greenbrook AcquisitionMay 7, 2025 | nasdaq.comNeuronetics Inc (STIM) Q1 2025 Earnings Call Highlights: Revenue Surge Amidst Margin ChallengesMay 7, 2025 | finance.yahoo.comNeuronetics, Inc. (STIM) Q1 2025 Earnings Call TranscriptMay 6, 2025 | seekingalpha.comNeuronetics (STIM) Reports Q1 Loss, Tops Revenue EstimatesMay 6, 2025 | zacks.comNeuronetics Reports First Quarter 2025 Financial and Operating ResultsMay 6, 2025 | globenewswire.comNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 5, 2025 | globenewswire.comNeuronetics (STIM) to Release Quarterly Earnings on TuesdayMay 1, 2025 | marketbeat.comWhy Neuronetics, Inc. (STIM) is Surging in 2025April 30, 2025 | msn.comNeuronetics to Announce Q1 2025 Results and Host Live Conference Call on May 6April 24, 2025 | msn.comNeuronetics to Report First Quarter 2025 Financial and Operating Results and Host Conference CallApril 22, 2025 | tmcnet.comNeuronetics Announces Expanded Coverage for NeuroStar TMS to Treat Adolescent DepressionApril 2, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookQualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWorkday Stock Price Implosion: An Automatic Buy for AI InvestorsBy Thomas Hughes | May 26, 2025View Workday Stock Price Implosion: An Automatic Buy for AI InvestorsVisa Q2 Earnings Top Forecasts, Adds $30B Buyback PlanBy Jeffrey Neal Johnson | May 3, 2025View Visa Q2 Earnings Top Forecasts, Adds $30B Buyback PlanSTIM, NPCE, DCTH, and SMLR Company DescriptionsDelcath Systems NASDAQ:DCTH$16.19 -0.22 (-1.34%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$16.18 -0.01 (-0.03%) As of 05/28/2025 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.NeuroPace NASDAQ:NPCE$12.46 -0.20 (-1.58%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$12.38 -0.09 (-0.68%) As of 05/28/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.Semler Scientific NASDAQ:SMLR$41.32 -2.07 (-4.77%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$42.52 +1.20 (+2.90%) As of 05/28/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Semler Scientific, Inc. provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. It also offers Insulin Insights, a software program that is used by a healthcare provider to optimize outpatient insulin dosing. The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, family practitioners, healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups and retailers. It offers its products through sales representatives and distributors. The company was incorporated in 2007 and is headquartered in Santa Clara, California.Neuronetics NASDAQ:STIM$3.85 -0.12 (-3.02%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$3.83 -0.02 (-0.55%) As of 05/28/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
